These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

189 related items for PubMed ID: 18087195

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Activated Akt signaling pathway in invasive ductal carcinoma of the breast: correlation with HER2 overexpression.
    Park SS, Kim SW.
    Oncol Rep; 2007 Jul; 18(1):139-43. PubMed ID: 17549359
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes.
    Kim MJ, Ro JY, Ahn SH, Kim HH, Kim SB, Gong G.
    Hum Pathol; 2006 Sep; 37(9):1217-26. PubMed ID: 16938528
    [Abstract] [Full Text] [Related]

  • 5. Basal-HER2 phenotype shows poorer survival than basal-like phenotype in hormone receptor-negative invasive breast cancers.
    Liu H, Fan Q, Zhang Z, Li X, Yu H, Meng F.
    Hum Pathol; 2008 Feb; 39(2):167-74. PubMed ID: 18045647
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Immunohistochemical identification of basal-type cytokeratins in invasive ductal breast carcinoma--relation with grade, stage, estrogen receptor and HER2.
    Kusińska R, Potemski P, Jesionek-Kupnicka D, Kordek R.
    Pol J Pathol; 2005 Feb; 56(3):107-10. PubMed ID: 16334976
    [Abstract] [Full Text] [Related]

  • 8. Clinical, histopathologic, and immunohistochemical features of microglandular adenosis and transition into in situ and invasive carcinoma.
    Khalifeh IM, Albarracin C, Diaz LK, Symmans FW, Edgerton ME, Hwang RF, Sneige N.
    Am J Surg Pathol; 2008 Apr; 32(4):544-52. PubMed ID: 18300793
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Alterations of estrogen receptors, progesterone receptors and c-erbB2 oncogene protein expression in ductal carcinomas of the breast.
    Hussein MR, Abd-Elwahed SR, Abdulwahed AR.
    Cell Biol Int; 2008 Jun; 32(6):698-707. PubMed ID: 18296077
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. RET finger protein expression in invasive breast carcinoma: relationship between RFP and ErbB2 expression.
    Tezel GG, Uner A, Yildiz I, Guler G, Takahashi M.
    Pathol Res Pract; 2009 Jun; 205(6):403-8. PubMed ID: 19232840
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Is triple negative a prognostic factor in breast cancer?
    Nishimura R, Arima N.
    Breast Cancer; 2008 Jun; 15(4):303-8. PubMed ID: 18369692
    [Abstract] [Full Text] [Related]

  • 20. [Expression of estrogen and progesterone receptors and HER-2 by breast cancer cells].
    Zaĭrat'iants OV, Kolobov SV, Akopian IG, Opalenov KV, Barsanova TG.
    Arkh Patol; 2004 Jun; 66(5):9-12. PubMed ID: 15575377
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.